J Rehabil Med. 2021 May 24;53(5):jrm00196. doi: 10.2340/16501977-2835.
To assess the effects of dextrose prolotherapy in patients with knee osteoarthritis on the levels of serum cartilage oligomeric proteinase and urinary C-terminal telopeptide of type II collagen, and on the Western Ontario McMaster Universities Index and numerical rating scale score for pain.
A randomized controlled trial, in which participants were randomly allocated into 2 groups, receiving injections of either hyaluronic acid or dextrose prolotherapy. The hyaluronic acid group received 5 injections, 1 each on weeks 1, 2, 3, 4 and 5, and the dextrose prolotherapy group received 3 injections, 1 each on weeks 1, 5 and 9. Serum cartilage oligomeric proteinase, urinary C-terminal telopeptide of type II collagen, Western Ontario McMaster Universities Index score, and numerical rating scale score for pain were measured at baseline and 3 weeks after the last injection. Comparative analysis was conducted using Wilcoxon test within groups and analysis of covariance (ANCOVA) test between groups.
A total of 47 participants (21 allocated to hyaluronic acid, 26 allocated to dextrose prolotherapy) completed the protocol. Both interventions resulted in significant improvements in numerical rating scale scores for pain, total Western Ontario McMaster Universities Index scores, and its subscales score. However, the dextrose prolotherapy outperformed hyaluronic acid in numerical rating scale score for pain and level of urinary C-terminal telopeptide of type II collagen, with score changes differences of 0.93 (p = 0.042) and 0.34 (p = 0.048), respectively. No significant changes in level of serum cartilage oligomeric proteinase were found in either group.
Dextrose prolotherapy is an alternative injection therapy for knee osteoarthritis, which was found to be associated with a significant reduction in urinary C-terminal telopeptide of type II collagen compared with hyaluronic acid injection. Neither injection method resulted in reduced serum cartilage oligomeric proteinase.
评估葡萄糖水疗法治疗膝骨关节炎患者对血清软骨寡聚蛋白酶和尿型Ⅱ胶原 C 末端肽水平、以及对西安大略和麦克马斯特大学骨关节炎指数(Western Ontario McMaster Universities Index,WOMAC)和疼痛数字评分量表(numerical rating scale,NRS)评分的影响。
本研究为一项随机对照试验,参与者被随机分为两组,分别接受透明质酸或葡萄糖水疗法注射。透明质酸组每周注射 1 次,共 5 次,分别在第 1、2、3、4 和 5 周;葡萄糖水疗法组每周注射 1 次,共 3 次,分别在第 1、5 和 9 周。在基线和最后一次注射后 3 周时,测量血清软骨寡聚蛋白酶、尿型Ⅱ胶原 C 末端肽、WOMAC 评分和 NRS 评分。使用组内 Wilcoxon 检验和组间协方差分析(analysis of covariance,ANCOVA)进行比较分析。
共有 47 名参与者(21 名分配至透明质酸组,26 名分配至葡萄糖水疗法组)完成了方案。两种干预措施均显著改善了 NRS 评分、WOMAC 总分及其各亚量表评分。然而,葡萄糖水疗法在 NRS 评分和尿型Ⅱ胶原 C 末端肽水平方面优于透明质酸,评分变化差异分别为 0.93(p=0.042)和 0.34(p=0.048)。两组血清软骨寡聚蛋白酶水平均无显著变化。
葡萄糖水疗法是治疗膝骨关节炎的一种替代注射疗法,与透明质酸注射相比,其可显著降低尿型Ⅱ胶原 C 末端肽水平。两种注射方法均未导致血清软骨寡聚蛋白酶降低。